Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Delamanid→

Delamanid Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
681492-22-8
Molecular formula
C25H25F3N4O6
Molecular weight
534.5 g/mol
Drug class
Nitro-dihydro-imidazooxazole antimycobacterial agentmycolic-acid synthesis inhibitor
Mechanism of action
A prodrug activated by the mycobacterial F420-dependent nitroreductase pathway. Its active metabolites inhibit synthesis of methoxy- and keto-mycolic acids, disrupting the mycobacterial cell wall.
Indications / reported uses
  • Part of an appropriate combination regimen for pulmonary multidrug-resistant tuberculosis (MDR-TB) in adults, adolescents, children and infants weighing at least 10 kg when an effective regimen cannot otherwise be composed because of resistance or tolerability; follow current national TB guidance

Sources: EMA Deltyba EPAR · EMA product information · Government of India — Guidelines for use of delamanid in drug-resistant TB · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Delamanid Environmental Risk Assessment (ERA) (the Delamanid ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.